{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:18:08Z","timestamp":1769854688187,"version":"3.49.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Possible dulaglutide-induced cholecystitis, with successful resumption of dulaglutide after cholecystectomy, is discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 72-year-old White man was started on dulaglutide for outpatient management of type 2 diabetes, in addition to his existing antihyperglycemic regimen of metformin, glipizide, pioglitazone, and insulin glargine. His glycated hemoglobin (HbA1c) concentration improved from 8.2% to 7.2% with the addition of dulaglutide. Furthermore, the use of dulaglutide did not lead to weight loss. After 16 months of treatment with dulaglutide, he presented to the emergency room with nausea, loss of appetite, and progressive sharp, nonradiating right upper quadrant pain. Based on symptom presentation, laboratory workup, and computed tomography scan results, acute cholecystitis was diagnosed. He underwent a cholecystectomy to remove what was found to be a gangrenous gallbladder. Per documented surgical dictation from the cholecystectomy, the gallbladder was removed, but portions of the biliary tree were left intact. The patient was continued on dulaglutide postoperatively without recurrence of bile stones, biliary tree disease, or abdominal symptoms at 8 months after initial cholecystitis incident.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A male patient with possible dulaglutide-induced cholecystitis was successfully continued on dulaglutide therapy post cholecystectomy without recurrent complications within the biliary tract.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab045","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T16:33:20Z","timestamp":1613579600000},"page":"684-688","source":"Crossref","is-referenced-by-count":3,"title":["Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy"],"prefix":"10.1093","volume":"78","author":[{"given":"Jared","family":"Butler","sequence":"first","affiliation":[{"name":"Drake University, Des Moines, IA"},{"name":"Central Iowa VAMC, Des Moines, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marysue","family":"Bjurstrom","sequence":"additional","affiliation":[{"name":"Central Iowa VAMC, Des Moines, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marceau","sequence":"additional","affiliation":[{"name":"Central Iowa VAMC, Des Moines, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"2021033109414352200_CIT0001","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care."},{"issue":"3","key":"2021033109414352200_CIT0002","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr."},{"issue":"1","key":"2021033109414352200_CIT0003","first-page":"27","article-title":"Management of blood glucose with noninsulin therapies in type 2 diabetes","volume":"92","author":"George","year":"2015","journal-title":"Am Fam Physician."},{"issue":"1133","key":"2021033109414352200_CIT0004","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad Med J."},{"key":"2021033109414352200_CIT0005","volume-title":"Package insert","author":"Trulicity","year":"2018"},{"issue":"7","key":"2021033109414352200_CIT0006","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2018-01008","article-title":"New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like-peptide-derived drugs","volume":"104","author":"Gether","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2021033109414352200_CIT0007","volume-title":"Package insert","author":"Tanzeum","year":"2017"},{"key":"2021033109414352200_CIT0008","volume-title":"Package insert","author":"Byetta","year":"2020"},{"key":"2021033109414352200_CIT0009","volume-title":"Package insert","author":"Victoza","year":"2019"},{"key":"2021033109414352200_CIT0010","volume-title":"Package insert","author":"Adlyxin","year":"2016"},{"key":"2021033109414352200_CIT0011","volume-title":"Package insert","author":"Ozempic","year":"2020"},{"issue":"2","key":"2021033109414352200_CIT0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jcpt.12373","article-title":"Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database","volume":"41","author":"Pizzimenti","year":"2016","journal-title":"J Clin Pharm Ther."},{"key":"2021033109414352200_CIT0013","article-title":"Diseases of the gallbladder and bile ducts","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Greenberger","year":"2020"},{"issue":"10","key":"2021033109414352200_CIT0014","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder disease with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med."},{"issue":"12","key":"2021033109414352200_CIT0015","first-page":"1005","article-title":"Complicated choledocholithiasis more common after cholecystectomy","volume":"5","author":"Spataro","year":"2018","journal-title":"EC Gastroenterol Dig Syst."},{"key":"2021033109414352200_CIT0016","article-title":"Open cholecystectomy","author":"Jones","year":"2020"},{"issue":"2","key":"2021033109414352200_CIT0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab045\/36297129\/zxab045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/8\/684\/36808190\/zxab045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/8\/684\/36808190\/zxab045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:01:27Z","timestamp":1617184887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/8\/684\/6140786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,2,17]]},"published-print":{"date-parts":[[2021,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab045","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,15]]},"published":{"date-parts":[[2021,2,17]]}}}